Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 1
1999 1
2003 1
2004 2
2005 2
2006 1
2007 1
2008 1
2009 2
2010 2
2011 1
2012 3
2013 1
2014 1
2016 3
2017 3
2018 4
2019 1
2020 5
2021 1
2022 1
2023 11
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Among authors: bieler s. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. Among authors: bieler s. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: bieler s. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Barratt J, Rovin B, Wong MG, Alpers CE, Bieler S, He P, Inrig J, Komers R, Heerspink HJL, Mercer A, Noronha IL, Radhakrishnan J, Rheault MN, Rote W, Trachtman H, Trimarchi H, Perkovic V; PROTECT investigators. Barratt J, et al. Among authors: bieler s. Kidney Int Rep. 2023 Mar 4;8(5):1043-1056. doi: 10.1016/j.ekir.2023.02.1086. eCollection 2023 May. Kidney Int Rep. 2023. PMID: 37180506 Free PMC article.
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
Trachtman H, Radhakrishnan J, Rheault MN, Alpers CE, Barratt J, Heerspink HJL, Noronha IL, Perkovic V, Rovin B, Trimarchi H, Wong MG, Mercer A, Inrig J, Rote W, Murphy E, Bedard PW, Roth S, Bieler S, Komers R. Trachtman H, et al. Among authors: bieler s. Kidney Int Rep. 2024 Jan 28;9(4):1020-1030. doi: 10.1016/j.ekir.2024.01.032. eCollection 2024 Apr. Kidney Int Rep. 2024. PMID: 38765567 Free PMC article.
Target product profile: diagnostic test for Trypanosoma brucei rhodesiense.
Priotto G, Franco JR, Lejon V, Büscher P, Matovu E, Ndung'u J, Biéler S, Mumba D, Van Reet N, Verlé P, Jamonneau V, Simarro PP, Ebeja AK, Sankara D, Dagne DA. Priotto G, et al. Among authors: bieler s. Bull World Health Organ. 2023 Aug 1;101(8):529-534. doi: 10.2471/BLT.23.290173. Epub 2023 Jun 26. Bull World Health Organ. 2023. PMID: 37529024 Free PMC article.
Target product profile: diagnostic test for Trypanosoma brucei gambiense.
Priotto G, Franco JR, Lejon V, Büscher P, Matovu E, Ndung'u J, Biéler S, Mumba D, Van Reet N, Verlé P, Jamonneau V, Simarro PP, Ebeja AK, Sankara D, Dagne DA. Priotto G, et al. Among authors: bieler s. Bull World Health Organ. 2023 Aug 1;101(8):535-540. doi: 10.2471/BLT.23.290172. Epub 2023 Jun 15. Bull World Health Organ. 2023. PMID: 37529027 Free PMC article.
Target product profile: Trypanosoma brucei gambiense test for low-prevalence settings.
Priotto G, Franco JR, Lejon V, Büscher P, Matovu E, Ndung'u J, Biéler S, Mumba D, Van Reet N, Verlé P, Jamonneau V, Simarro PP, Ebeja AK, Sankara D, Dagne DA. Priotto G, et al. Among authors: bieler s. Bull World Health Organ. 2023 Aug 1;101(8):541-545. doi: 10.2471/BLT.23.290176. Epub 2023 Jun 26. Bull World Health Organ. 2023. PMID: 37529025 Free PMC article.
Target product profile: Trypanosoma brucei gambiense test to verify elimination.
Priotto G, Franco JR, Lejon V, Büscher P, Matovu E, Ndung'u J, Biéler S, Mumba D, Van Reet N, Verlé P, Jamonneau V, Simarro PP, Ebeja AK, Sankara D, Dagne DA. Priotto G, et al. Among authors: bieler s. Bull World Health Organ. 2023 Aug 1;101(8):522-528. doi: 10.2471/BLT.23.290177. Epub 2023 Jun 15. Bull World Health Organ. 2023. PMID: 37529018 Free PMC article.
53 results